RegeneRx Biopharmaceuticals, Inc. RGRX
Set alert
0.00 USD 0.00 0.00%
At close · Oct 30
0.161 Day range 0.161
0.0002 52-week range 0.163
- YTD
- +266.67%
- 1 year
- +450.00%
- Open
- 0.161
- Prev close
- 0.0011
- Mkt cap
- 1.65K
- Vol
- 252
- Avg vol
- 47
- EPS
- -0.71
- P/E
- 0.00
More statistics
- Low
- 0.161
- High
- 0.161
- Earnings
- Jan 2, 2023
Next earnings
Jan 2, 2023
Expected Jan 2, 2023. Consensus EPS estimate 0.00.
Financials — quick view
RGRX Revenue — quarterly 19.19K
RGRX Net income — quarterly -385.20K
RGRX EPS — quarterly 0.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 2, 2023 | Sep 1, 2022 | 0.00 | — | — | — |
| Nov 15, 2021 | Sep 1, 2021 | 0.00 | 0.00 | — | — |
| Aug 6, 2021 | Jun 1, 2021 | 0.00 | 0.00 | — | — |
News
- RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations
- RegeneRx Receives Stockholder Approval for Reverse Stock Split
- RegeneRx To Extend Consent Solicitation Vote
- Researchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with Sepsis
- RegeneRx Issues Letter To Stockholders
- RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome
- RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement
- RegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private Placement
- RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome
- RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial
Your note
Sign in to keep a note on RGRX — it syncs with the Stock Master app.